Paratesticular_rhabdomyosarcoma:_results_of_therapy_in_18_cases._The_management_of_paratesticular_rhabdomyosarcoma_has_evolved_more_slowly_than_that_for_testicular_germ_cell_tumors,_mainly_due_to_its_lower_incidence_and_the_lack_of_standardized_treatment_protocols._With_gradual_refinements_in_staging_and_therapy_the_prognosis_has_improved._Between_1960_and_1988,_18_patients_2_to_18_years_old_were_treated_at_the_Children's_Hospital._Management_consisted_of_inguinal_orchiectomy,_staging_evaluation_and_retroperitoneal_lymph_node_dissection,_followed_by_chemotherapy_and_radiotherapy_according_to_the_stage_of_the_disease._In_11_patients_(61%)_the_disease_was_confined_to_the_scrotum,_while_7_presented_with_spread_to_the_retroperitoneal_lymph_nodes,_including_3_children_with_more_distant_metastases._Histological_study_revealed_predominantly_embryonal_characteristics_except_for_1_alveolar_cell_type._Chemotherapy_consisted_of_actinomycin_D_in_2_patients,_vincristine,_actinomycin_D_and_cyclophosphamide_in_2,_pulse_vincristine,_actinomycin_D_and_cyclophosphamide_in_10,_and_doxorubicin_plus_vincristine,_actinomycin_D_and_cyclophosphamide_in_4._A_total_of_17_patients_remain_free_of_disease_(median_followup_4_years)_with_1_death._The_actuarial_survival_without_relapse_and_over-all_survival_rate_are_89_and_94%,_respectively._We_conclude_that_paratesticular_rhabdomyosarcoma_represents_a_favorable_subgroup_of_rhabdomyosarcoma.